Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7380297 | 1.00 | ACE (0.54) | ACEKMT2AHTRA1AGTR2UCHL1 | |
| SCHEMBL12646680 | 1.00 | ACE (0.54) | ACEKMT2AHTRA1AGTR2UCHL1 | |
| SCHEMBL8642743 | 1.00 | ACE (0.54) | ACEKMT2AHTRA1AGTR2UCHL1 | |
| SCHEMBL9542869 | 1.00 | ACE (0.54) | ACEKMT2AHTRA1AGTR2UCHL1 | |
| SCHEMBL3194307 | 1.00 | ACE (0.54) | ACEKMT2AHTRA1AGTR2UCHL1 | |
| SCHEMBL6848107 | 0.90 | CYP1A2 (0.45) | ACEKMT2AHTRA1CYP1A2POLB | |
| SCHEMBL6848112 | 0.90 | CYP1A2 (0.45) | ACEKMT2AHTRA1CYP1A2POLB | |
| SCHEMBL6847765 | 0.89 | NR1H2 (0.44) | ACEKMT2AHTRA1UCHL1CYP1A2 | |
| SCHEMBL700092 | 0.89 | NR1H2 (0.44) | ACEKMT2AHTRA1UCHL1CYP1A2 | |
| SCHEMBL6847598 | 0.89 | NR1H2 (0.44) | ACEKMT2AHTRA1UCHL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015003723-A1 | SUBSTITUTED 4-PROLINE DERIVATIVES AS IGLUR ANTAGONISTS | Københavns Universitet (DK) | 2015-01-15 | — | — | WO | disclosed |
| US-6770741-B1 | USEFUL IN TREATING CONDITIONS AND DISEASES OF A MAMMAL AND HUMAN IN WHICH AN EXCESS OF BRADYKININ OR RELATED KININS ARE PRODUCED OR INJECTED SUCH AS BY INSECT BITES | SCIOS INC. | 2004-08-03 | — | — | US | disclosed |
| US-6288036-B1 | ANTIINFLAMMATORY, ANTIASTHMATIC, ANTIALLERGEN, AND ANALGESIC AGENTS; ARGININE-CONTAINING NONA- OR DECAPEPTIDES | SCIOS INC. | 2001-09-11 | — | — | US | disclosed |
| EP-0618810-B1 | BRADYKININ ANTAGONIST PEPTIDES | SCIOS NOVA INC (US) | 2001-07-04 | — | — | EP | disclosed |
| EP-0618809-B1 | BRADYKININ TYPE PEPTIDES | SCIOS NOVA INC (US) | 1998-08-19 | — | — | EP | disclosed |
| US-5385889-A | Substitution of L-proline at the 7-position of the peptide hormone with a D-configuration hydroxyproline ether or thioether converts agonist into antagonist | SCIOS NOVA INC. (US) | 1995-01-31 | — | — | US | disclosed |
| EP-0618810-A4 | BRADYKININ ANTAGONIST PEPTIDES. | SCIOS NOVA INC (US) | 1994-12-07 | — | — | EP | disclosed |
| EP-0618810-A1 | BRADYKININ ANTAGONIST PEPTIDES | SCIOS NOVA INC. (US) | 1994-10-12 | — | — | EP | disclosed |
| EP-0618809-A1 | BRADYKININ TYPE PEPTIDES | SCIOS NOVA INC. (US) | 1994-10-12 | — | — | EP | disclosed |
| EP-0618809-A4 | BRADYKININ TYPE PEPTIDES. | SCIOS NOVA INC (US) | 1994-07-28 | — | — | EP | disclosed |
| WO-1992018155-A1 | BRADYKININ TYPE PEPTIDES | NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) | 1992-10-29 | — | — | WO | disclosed |
| WO-1992018156-A1 | BRADYKININ ANTAGONIST PEPTIDES | NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) | 1992-10-29 | — | — | WO | disclosed |